Braidwell LP Acquires 836,210 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Braidwell LP lifted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 40.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,894,513 shares of the company’s stock after purchasing an additional 836,210 shares during the quarter. Kiniksa Pharmaceuticals comprises approximately 2.1% of Braidwell LP’s portfolio, making the stock its 18th largest holding. Braidwell LP’s holdings in Kiniksa Pharmaceuticals were worth $72,334,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after buying an additional 157,741 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $675,000. Millennium Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $2,438,000. Finally, Semanteon Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $551,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Up 1.3 %

NASDAQ:KNSA opened at $22.32 on Friday. The firm has a fifty day simple moving average of $24.02 and a 200-day simple moving average of $22.92. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $15.52 and a 12 month high of $28.15. The company has a market capitalization of $1.61 billion, a P/E ratio of -159.42 and a beta of 0.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The company had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares in the company, valued at approximately $1,359,232.56. This trade represents a 53.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total value of $437,325.00. Following the completion of the transaction, the chief operating officer now owns 116,975 shares of the company’s stock, valued at approximately $2,923,205.25. This trade represents a 13.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 95,192 shares of company stock worth $2,479,390 in the last ninety days. Insiders own 54.57% of the company’s stock.

Analyst Upgrades and Downgrades

KNSA has been the subject of a number of analyst reports. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.